ArticleInflammation2026
Keratinocyte-derived Exosomal LKB1 Drives Vitiligo Progression by Activating CD8
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratinocytes are increasingly recognized as active regulators of immune activation and tissue-specific recruitment of CD8⁺ T cells in vitiligo. While keratinocyte-derived exosomes have been implicated in disease pathogenesis, their role in modulating CD8⁺ T cell–mediated cytotoxicity against melanocytes remains unclear. In this study, we successfully isolated exosomes (Vexo) from primary keratinocytes of vitiligo lesional skin and demonstrated their ability to significantly activate CD8⁺ T cells, thereby promoting disease progression. Further analysis revealed a specific enrichment of liver kinase B1 (LKB1) within Vexo, along with its elevated expression in vitiligo patient skin compared to normal controls. Mechanistically, Vexo facilitates the transfer of LKB1 into CD8⁺ T cells and activates them via the LKB1/AMPK signaling pathway. Notably, Vexo-activated CD8⁺ T cells secrete IFN-γ, which in turn induces LKB1 transcription in keratinocytes through STAT1 signaling, establishing a positive feedback loop that amplifies immune activation and exacerbates vitiligo pathogenesis. Together, our results identify keratinocyte-derived exosomal LKB1 as a critical driver of CD8⁺ T cell activation and vitiligo progression, unveiling a pathogenic keratinocyte–T cell feedback circuit and nominating LKB1 as a potential therapeutic target for vitiligo intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.